Join us for ongoing discussions with our clinician-bloggers,
HIV and ID Observations
An ongoing dialogue on HIV/AIDS, infectious diseases,
all matters medical, and some not so medical
Recent Posts
Long-Acting Injectable HIV Therapy for People Who Won’t Take ART? • August 8, 2022
HIV treatment is so spectacularly effective that you might be surprised to hear that some people with HIV still have uncontrolled viral replication. We HIV clinicians watch with frustration and sadness as they experience progressive immunodeficiency, complications from advanced HIV disease, hospitalizations, and HIV-related deaths. Plus, while viremic, they continue to risk transmitting the virus […]
Insights on Residency Training
Notes from chief residents in family and internal medicine
Recent Posts
Uncertainty in Medicine — The “July Effect” and Beyond • August 4, 2022 • Khalid A. Shalaby, MBBCh
When I first started residency, I was uncertain and hesitant with most of my clinical decisions. As medical students, we gain considerable knowledge through our medical school curriculum. But gaining knowledge and applying it to practice are two different sets of skills. Because I followed medical school graduation by a hiatus doing bench research, I […]
Clinical Conversations
Audio podcasts featuring the week's news,
plus your comments and pertinent interviews
Recent Posts
Podcast 299: Lung cancer and atezolizumab — results from the IMpower010 trial • August 9, 2022
A VIDEO RECORDING OF THIS INTERVIEW IS AVAILABLE HERE. Interim results on overall survival in phase 3 of the IMpower010 trial were presented at this year’s meeting of the International Assosciation for the Study of Lung Cancer (IASLC). As part of the NEJM Group’s coverage of the conference, Christine Sadlowski interviewed the presenter, Dr. Enriqueta Felip. […]
The post Podcast 299: Lung cancer and atezolizumab — results from the IMpower010 trial first appeared on Clinical Conversations.The views and opinions expressed in these blogs are not necessarily those of NEJM Journal Watch or NEJM Group.